2-苄基吡咯烷 | 35840-91-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-苄基吡咯烷
• 英文名称: 2-benzylpyrrolidine
• CAS: 35840-91-6
• 化学式: C₁₁H₁₅N
• mdl: MFCD01631839
• 分子量: 161.247
• InChiKey: NKHMSOXIXROFRU-UHFFFAOYSA-N

物化性质

• 沸点：
  96-97 °C(Press: 2 Torr)
• 密度：
  0.988±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Benzylpyrrolidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Benzylpyrrolidine
CAS number: 35840-91-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H15N
Molecular weight: 161.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-苄基吡咯烷 在 氢气 、 硝酸 作用下， 以 (2S)-N-methyl-1-phenylpropan-2-amine hydrate 、 乙醇 、 硫酸 为溶剂， 生成 1-acetyl-2-(4-aminobenzyl)pyrrolidine
  参考文献：
  名称：

  2-(Nuclearly-substituted)benzylpyrrolidines

  摘要：

  2-苄基吡咯烷酮在苄基环上带有1至4个核取代基，具有药理活性，特别是对于中枢神经系统、血压和对于温血动物的疼痛感觉。它们可以通过还原适当的2-苄基吡咯烷酮合成，并根据已建立的传统技术制成药物组合物。

  公开号：

  US04279918A1
• 作为产物：
  描述：

  肉桂基氯 在 lithium aluminium tetrahydride 、 ammonium cerium (IV) nitrate 、 (4,4'-di-tert-butyl-2,2'-dipyridyl)-bis-(2-phenylpyridine(-1H))-iridium(III) hexafluorophosphate 、 甲基溴化镁 、 potassium carbonate 、 sodium iodide 、 sodium chloride 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 水 、 二甲基亚砜 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 138.5h， 生成 2-苄基吡咯烷
  参考文献：
  名称：

  带有胺自由基阳离子的催化烯烃加氢胺化：直接形成 C-N 键的光氧化还原方法

  摘要：

  虽然用胺自由基阳离子进行烯烃胺化是形成 CN 键的经典方法，但利用简单 2° 胺前体的催化变体在很大程度上仍未开发。在此，我们报告了一种新的可见光光氧化还原方案，用于芳基烯烃的分子内抗马尔科夫尼科夫加氢胺化，该方案通过催化生成的胺自由基中间体进行。机理研究与涉及胺氧化的过程一致，包括通过电子转移、限制周转的 CN 键形成和第二个电子转移步骤以减少以碳为中心的自由基，从而使整个过程氧化还原中性。一系列结构多样的 N-芳基杂环可以在比传统的基于胺的方案所需的条件温和得多的条件下以良好到优异的产率制备。

  DOI：

  10.1021/ja5056774

文献信息

• Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington’s Disease
  作者：Amanda Van de Poël、Leticia Toledo-Sherman、Perla Breccia、Roger Cachope、Jennifer R. Bate、Ivan Angulo-Herrera、Grant Wishart、Kim L. Matthews、Sarah L. Martin、Marcus Peacock、Amy Barnard、Helen C. Cox、Graham Jones、George McAllister、Huw Vater、William Esmieu、Cole Clissold、Marieke Lamers、Philip Leonard、Rebecca E. Jarvis、Wesley Blackaby、Maria Eznarriaga、Ovadia Lazari、Dawn Yates、Mark Rose、Sung-Wook Jang、Ignacio Muñoz-Sanjuan、Celia Dominguez

  DOI：10.1021/acs.jmedchem.1c00114

  日期：2021.4.22

  group has recently shown that brain-penetrant ataxia telangiectasia-mutated (ATM) kinase inhibitors may have potential as novel therapeutics for the treatment of Huntington’s disease (HD). However, the previously described pyranone-thioxanthenes (e.g., 4) failed to afford selectivity over a vacuolar protein sorting 34 (Vps34) kinase, an important kinase involved with autophagy. Given that impaired autophagy

  我们的小组最近表明，脑渗透性共济失调毛细血管扩张突变（ATM）激酶抑制剂可能具有作为治疗亨廷顿舞蹈病（HD）的新型疗法的潜力。但是，先前描述的吡喃酮-噻吨酮（例如，4）未能提供对液泡蛋白分选34（Vps34）激酶（一种与自噬有关的重要激酶）的选择性。鉴于自噬受损已被提出作为神经退行性疾病（如HD）的致病机制，因此对Vps34的选择性成为我们程序的重要目标。在这里，我们报告了通过使用Vps34-ATM蛋白嵌合体的X射线晶体结构成功完成了ATM在Vps34上的选择性优化，其中Vps34 ATP结合位点发生突变，近似于ATM激酶。由于选择性优化过程而产生的吗啉代-吡啶酮和吗啉代-嘧啶酮系列具有较高的ATM效能和良好的口服生物利用度，并且分子量较低，亲脂性降低，水溶性较高，
• [EN] HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS POUR LEUR UTILISATION
  申请人：SPINIFEX PHARM PTY LTD

  公开号：WO2013102242A1

  公开（公告）日：2013-07-11

  The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

  本发明涉及用于拮抗血管紧张素II型2（AT2）受体的杂环化合物。更具体地，本发明涉及吡咯烷和氮杂环丙烷化合物，含有它们的组合物以及它们在治疗或预防与AT2受体功能相关的疾病或疾病的方法中的使用，包括神经病性疼痛、炎症性疼痛、与神经元过敏、神经传导速度受损、细胞增殖紊乱、骨吸收和骨形成之间失衡以及与异常神经再生相关的疾病。
• [EN] PYRROLIDIN-3-YL COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] COMPOSES PYRROLIDIN-3-YLE UTILES EN TANT QU'INHIBITEURS DE LA BETA-SECRETASE POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：MERCK & CO INC

  公开号：WO2006002004A1

  公开（公告）日：2006-01-05

  The present invention is directed to pyrrolidin-3-yl derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及吡咯烷-3-基衍生物化合物，这些化合物是β-分泌酶的抑制剂，并且在治疗涉及β-分泌酶的疾病，如阿尔茨海默病中有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗涉及β-分泌酶的这类疾病中使用这些化合物和组合物。
• [EN] ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE KINASE ATM ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：CHDI FOUNDATION INC

  公开号：WO2021113506A1

  公开（公告）日：2021-06-10

  Provided are certain ATM kinase inhibitors of Formula (I). Also provided herein are compositions of such compounds, and methods of their use.

  提供了某些Formula (I)的ATM激酶抑制剂。本文还提供了这些化合物的组合物，以及它们的使用方法。
• [DE] NEUE CARBONSÄUREAMIDE, DEREN HERSTELLUNG UND DEREN VERWENDUNG ALS ARZNEIMITTEL<br/>[EN] NOVEL CARBOXAMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS<br/>[FR] NOUVEAUX AMIDES D'ACIDE CARBOXYLIQUE, LEUR PRODUCTION ET LEUR UTILISATION EN TANT QUE MEDICAMENTS
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2004056784A1

  公开（公告）日：2004-07-08

  Gegenstand der vorliegenden Erfindung sind neue substituierte Carbonsäureamide der allgemeinen Formel (I), in der A, B und R1 bis R5 wie in Anspruch 1 definiert sind, deren Tautomere, deren Enantiomere, deren Diastereomere, deren Gemische und deren Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren oder Basen, welche wertvolle Eigenschaften aufweisen. Die Verbindungen der obigen allgemeinen Formel (I) sowie deren Tautomere, deren Enantiomere, deren Diastereomere, deren Gemische und deren Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren oder Basen, und deren Stereoisomere weisen wertvolle pharmakologische Eigenschaften auf, insbesondere eine antithrombotische Wirkung und eine Faktor Xa-inhibierende Wirkung.

  本发明涉及一种新的取代羧酰胺，其通式为(I)，其中A、B和R1至R5如权利要求1所定义，其互变异构体、对映异构体、非对映异构体、混合物和盐，特别是其与无机或有机酸或碱形成的生理相容盐，具有有价值的特性。上述通式(I)的化合物及其互变异构体、对映异构体、非对映异构体、混合物和盐，特别是其与无机或有机酸或碱形成的生理相容盐，以及其立体异构体具有有价值的药理特性，特别是抗血栓作用和Xa因子抑制作用。